Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more
Dr. Abbey Presented Study Results of Two Investigational Wet AMD Treatments at Clinical Trials Summit
This past weekend, Texas Retina’s Director of Clinical Research for Dallas Ashkan M. Abbey, MD, led two presentations at the annual Clinical Trials at the Summit (CTS) meeting in Las Vegas, which
read more
Dr. Wang Featured in New Retina Radio Podcast
Texas Retina’s Robert C. Wang, MD, was interviewed about his presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting for an episode of the New Retina Radio podcast
read more Dr. Wang Presented Study Results of New Wet AMD Treatment Approach at the ARVO 2025 Meeting
On May 9, 2025, Texas Retina’s Robert C. Wang, MD, presented “Top Line Results from ODYSSEY: A Phase IIb Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration” at
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
Texas Retina Research Team Publishes New Study on Wet AMD Treatment
Texas Retina’s Ashkan Abbey, MD; Paige Abril, BS; and Rachel McCullough, BS, recently published a retrospective study in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina titled, “Outcomes of Intravitreal Aflibercept
read more
Dr. Abbey Reports on New Method to Measure Retinal Fluid After Treatment with Faricimab for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored an article in the medical journal Eye on the use of a novel deep-learning algorithm to quantify retinal fluid changes in patients treated with
read more
Dr. Coors Treats First Patient in DAYBREAK Clinical Trial of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer for Wet AMD
Texas Retina’s Lori E. Coors, MD, recently enrolled and treated the first patient in the Phase III DAYBREAK trial evaluating an intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more